mRNA therapeutics expand beyond vaccines to oncology/genetic diseases, but delivery (protecting mRNA, enabling cytoplasmic entry) is key—non-viral nanoplatforms like LNPs/polymers tackle this.
Creative Biolabs offers custom mRNA delivery services via lipid engineering, polymer chemistry, and eVLP design. We tailor high-performance nanosystems to your mRNA payload, ensuring safety, stability, and efficacy to boost clinical viability.
Discover How We Can Help - Request a ConsultationCreative Biolabs offers four core development platforms, ensuring a solution perfectly matched to your biological and therapeutic requirements.
Fig.1 The main mRNA delivery platform based on nanoparticles.1
Lipid-based vectors, including Lipoplexes and next-generation Lipid Nanoparticles (LNPs), are the industry standard due to their exceptional ability to encapsulate mRNA and facilitate endosomal escape, primarily through the use of ionizable lipids. We customize the lipid component ratio, optimizing head-group chemistry and tail length based on the size (e.g., for standard mRNA versus larger saRNA) and chemical modifications of your transcript.
Polymer-based systems, such as Polyplexes and Micelleplexes, offer superior chemical tunability. We utilize various biocompatible polymers to create stable nanoparticles that can be precisely tailored for controlled release kinetics and specific surface functionalization. This approach is ideal for applications demanding high stability and the integration of specific targeting ligands for improved delivery specificity.
The Hybrid Vector platform combines the best features of lipids and polymers, resulting in complex structures like Lipopolyplexes and Cationic Nanoemulsions. These systems are designed to maximize both stability (often provided by a polymeric core) and highly efficient cellular entry (via a lipid or lipid-like shell). Hybrid vectors are essential for complex applications that require simultaneous optimization of multiple physicochemical properties.
Enveloped Virus-Like Particles (eVLPs) are advanced, non-replicating scaffolds that naturally mimic the fusogenic properties of viruses (e.g., LVLPs, VEEVLPs). They offer a highly efficient, biomimetic pathway for delivery into difficult-to-transfect cell types, yielding potent in vivo results, particularly for high-immunogenicity vaccines where the structural components can act as intrinsic adjuvants.
Rigorous characterization is integral to our service. We provide a detailed analysis of Lipid Nanoparticle-formulated Drug Characterization, including size, PDI, Zeta Potential, and encapsulation efficiency, ensuring that the final optimized vector meets all quality control specifications necessary for preclinical success.
Our structured, multi-stage workflow provides clarity and efficiency, ensuring that the final delivery system is fully customized and optimized for your unique payload.
To initiate the bespoke design process, clients typically provide:
Leverage computational modeling to select optimal lipid/polymer ratios and targeting moieties based on payload and target cell traits, delivering an initial vector architecture, optimized parameters (e.g., N:P ratio), and ready-to-synthesize raw materials.
Upon project completion, clients receive specific documentation and materials:
The typical timeframe for this service ranges from 8 to 16 weeks, depending on the complexity of the chosen vector (e.g., LNP vs. custom eVLP) and the scope of the in vivo testing required for the therapeutic target.
As a partner to leading biology experts, Creative Biolabs' Custom mRNA Delivery Vehicle Development Services are engineered for unparalleled therapeutic precision and scalability:
End-to-End Delivery Solution
A single, integrated service covering vehicle design, proprietary component synthesis, payload formulation (Lipid, Polymer, Hybrid, eVLP), and rigorous physicochemical characterization, minimizing technical friction and accelerating your timeline.
Payload-Specific Customization
We go beyond standard formulations, optimizing vector composition (e.g., ionizable lipid pKa, N:P ratio) based precisely on your mRNA transcript size, modifications (e.g., saRNA compatibility), and expression kinetics for maximized in vivo efficacy.
Scalable and Robust Formulation
Development of processes using advanced techniques (like microfluidics) that are reproducible and scalable, ensuring a smooth transition from R&D to preclinical and large-scale GMP-compliant manufacturing.
Advanced Quality Assurance
Implementation of a Quality-by-Design (QbD) approach and stringent process controls, providing comprehensive CMC-ready documentation and data packages (including stability, PDI, and Zeta Potential) essential for regulatory submission.
Targeting & Efficacy Tuning
Expertise in surface functionalization and component selection to tune the nanosystem for specific cell targeting and controlled immunogenic profiles (immune-evading vs. immune-activating), giving you control over the therapeutic environment.
A: The optimal vehicle depends entirely on your antigen and target immune cell. While LNPs are widely used, a custom eVLP might offer superior T-cell activation due to its biomimetic structure. Conversely, a mannose-targeted LNP can drastically improve DC uptake.
A: Stability is addressed at multiple stages. First, through component selection (e.g., specific stabilizing PEGylation); second, through fine-tuning formulation parameters to achieve optimal Zeta Potential and PDI (uniformity); and third, by providing detailed QC protocols designed to predict long-term stability and guide your CMC strategy.
A: Yes. saRNA presents a unique challenge due to its large size. We specialize in designing custom Polymer and Hybrid vectors that can efficiently condense and protect these larger transcripts, enabling strong, sustained antigen expression from a lower dose.
A: Custom delivery vehicles, particularly eVLPs and highly optimized Polyplexes, are often designed to overcome inherent cellular resistance better than bulk methods like electroporation, which can damage cells and lack targeting specificity in vivo. Our vectors are engineered for high-efficiency cellular entry and endosomal escape, making them ideal for challenging cells.
Creative Biolabs offers unparalleled expertise in synthesizing, modifying, and delivering your mRNA therapeutic. Our customized vector solutions, covering Lipid, Polymer, Hybrid, and eVLP platforms, accelerate your project by providing high stability, superior targeting, and maximal efficacy, transforming your scientific discovery into a viable clinical product.
Contact Our Team for More Information and to Discuss Your ProjectReference
